Find Novel Drugs for Cardiology/Vascular Diseases under Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Everolimus

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESPRIT BTK

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 03, 2020

            Details:

            This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PMC-403

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: PMC-403

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: NIH

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 18, 2020

            Details:

            Under this agreement, Kirk M. Druey, M.D., and colleagues at the NIAID will investigate PMC-403 in preclinical models. PharmAbcine will discuss potential clinical development in collaboration with the NIH as the study progresses.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Autonomic regulation therapy

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vitaria

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 12, 2020

            Details:

            LivaNova will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sirolimus

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: BuMA Suprem

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 08, 2020

            Details:

            SINOMED completed 1-year follow-up in the PIONEER-III trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). BuMA Supreme is Sinomed's second-generation DES with eG Coating, biodegradable polymer and sirolimus drug.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ESI human embryonic stem cells

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESI hESC

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: AgeX Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 16, 2020

            Details:

            The agreement is a key step in AgeX’s licensing and collaboration strategy to facilitate industry and academic access to its hESC lines, its PureStem® cell derivation and manufacturing platform, and its UniverCyte™ immunotolerance technology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Immune globulin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Norton Heart & Vascular Institute in Louisvill

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 28, 2020

            Details:

            Octapharma USA is donating Octagam® 10% and cutaquig® 16.5%, the company’s intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), for the study. BioMatrix will be donating patient education, including instruction in subcutaneous injection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): miRNA-125b

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2020

            Details:

            The micro-RNA was identified as suitable for further development based on favorable pharmacokinetic results as well as pharmacodynamic data at the molecular level.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antisense oligonucleotide therapies

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Lipigon

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 23, 2020

            Details:

            Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cardiomyocytes

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: BlueRock Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 21, 2020

            Details:

            Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.